MPM Oncology Innovations Fund GP LLC — SEC Form 4 filings
SEC reporting owner CIK 1857903. 11 Form 4 filings on record with FilingPulse; latest filed 2026-01-14.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2025-04-30 to 2026-01-14. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 1,112,777 shares, $20,029,986 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 29 legs across 10 filings — 1,938,945 shares, $2,227,963 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 9.
- Largest priced transaction: purchase of 1,112,777 shares @ $18.00 ($20,029,986) in Aktis Oncology, Inc., filed 2026-01-14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | 10% owner | 1 | 1 leg · 1,112,777 sh · $20,029,986 | — | 6 |
| Werewolf Therapeutics, Inc. (HOWL) | — | 10 | — | 29 legs · 1,938,945 sh · $2,227,963 | 3 |
Form 4 filings — MPM Oncology Innovations Fund GP LLC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-01-14 | 4 | Aktis Oncology, Inc. (AKTS) jointly with MPM BIOVENTURES 2018, L.P., EVNIN LUKE, MPM BIOVENTURES 2018 (B), L.P., MPM BioVentures 2018 LLC, MPM BioVentures 2018 GP LLC, MPM ASSET MANAGEMENT INVESTORS BV2018 LLC, MPM ONCOLOGY INNOVATIONS FUND LP | Conversion (C): 1,314,262 · Conversion (C): 5,914,197 · Conversion (C): 1,577,119 · Purchase (P): 1,112,777 @ $18 · Conversion (C): 5,000,000 (derivative) @ $0 · Conversion (C): 22,500,000 (derivative) @ $0 · +1 more | EDGAR |
| 2025-12-04 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 59,277 @ $0.89 · Sale (S): 57,225 @ $0.87 · Sale (S): 83,230 @ $0.97 | EDGAR |
| 2025-12-01 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 60,733 @ $0.98 · Sale (S): 20,277 @ $0.99 · Sale (S): 60,917 @ $0.94 | EDGAR |
| 2025-11-25 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 64,331 @ $0.83 · Sale (S): 88,802 @ $0.98 · Sale (S): 42,533 @ $0.92 | EDGAR |
| 2025-11-20 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 52,627 @ $0.93 · Sale (S): 66,324 @ $0.94 · Sale (S): 41,152 @ $0.89 | EDGAR |
| 2025-11-17 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 90,951 @ $0.98 · Sale (S): 61,640 @ $0.93 · Sale (S): 57,061 @ $0.95 | EDGAR |
| 2025-11-12 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 68,480 @ $1.11 · Sale (S): 48,570 @ $1.18 · Sale (S): 55,810 @ $1.14 · Sale (S): 40,669 @ $1.09 | EDGAR |
| 2025-11-06 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 140,488 @ $1.22 · Sale (S): 47,950 @ $1.22 · Sale (S): 54,452 @ $1.21 | EDGAR |
| 2025-11-03 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 86,936 @ $1.43 · Sale (S): 114,044 @ $1.28 · Sale (S): 94,063 @ $1.29 | EDGAR |
| 2025-10-29 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Sale (S): 72,709 @ $1.72 · Sale (S): 69,068 @ $1.64 · Sale (S): 134,240 @ $1.55 | EDGAR |
| 2025-04-30 | 4 | Werewolf Therapeutics, Inc. (HOWL) jointly with GADICKE ANSBERT, MPM ONCOLOGY INNOVATIONS FUND LP, UBS Oncology Impact Fund L.P., Oncology Impact Fund (Cayman) Management L.P., MPM BioImpact LLC, MPM ASSET MANAGEMENT LLC | Option exercise/expiry (X): 50,873 @ $0.09 · Sale (S): 4,386 @ $1.05 · Option exercise/expiry (X): 8,031 (derivative) @ $0 · Option exercise/expiry (X): 42,842 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1857903 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →